Formulation Of Tablet Of Ivermectin Co-Crystal For Enhancement Of Solubility And Other Physical Properties

Authors

  • Shivraj Popat Jadhav, Dhananjay Machhindra Patil, Deepak Devidas Sonawane, Pratik Dilip Patil, Prasad Gorakshanath Ghugarkar, Mohammed Saad

DOI:

https://doi.org/10.47750/pnr.2023.14.S01.60

Abstract

Ivermectin is an anti-parasite medication used to treat head lice, onchocerciasis, strongyloidiasis, ascariasis, trichuriasis, and enterobiasis. Ivermectin belongs to the biopharmaceutical classification system [BCS] class II because it is having low solubility and high permeability. The present study focuses to increase the solubility of Ivermectin by use of the co-crystal technique. Co-crystals comprise a multicomponent system of active pharmaceutical ingredient [API] with a stoichiometric amount of a pharmaceutically acceptable co-former incorporated in the crystal lattice. Co-crystals of Ivermectin with different co-formers like fumaric acid, succinic acid, glutaric acid and cinnamic acid were prepared in 1:1 stochiometric ratio. Solvent assisted grinding method was used for the formation of co-crystals. Different characteristics of plain drug Ivermectin like melting point, IR, DSC, XRD, and solubility profile was compared with formed co-crystal. Among four co-crystals obtained co-crystal of Ivermectin with co-former Cinnamic acid showed an increase in solubility. Hence Ivermectin-Cinnamic acid co-crystals were further characterized. A Ivermectin-Cinnamic acid co-crystal compatibility study was performed with various excipients. Tablets were formulated by the wet granulation method and compared for in-vitro drug release studies with the marketed formulation. From the studies, it can be concluded that Ivermectin-Cinnamic acid co-crystals show higher drug release.  

Downloads

Published

2023-01-13 — Updated on 2023-01-14

Versions

Issue

Section

Articles

How to Cite

Formulation Of Tablet Of Ivermectin Co-Crystal For Enhancement Of Solubility And Other Physical Properties. (2023). Journal of Pharmaceutical Negative Results, 513-520. https://doi.org/10.47750/pnr.2023.14.S01.60 (Original work published 2023)